The Federal Government has budgeted N10.6 billion for the transportation of COVID-19 vaccines to the 36 states of the federation and the federal capital territory FCT.
A total of N12.7 billion was budgeted as cost of transportation for the vaccine, procurement of PPE and AEFI kits.
In the document containing the budget details, Kano state has the highest budgetary allocation with N685.4million, while Lagos state, the epicenter of the pandemic, earmarked N558.6million for the transportation of the vaccine.
On Friday, Nigeria commenced its COVID-19 vaccination with doses of the AstraZeneca COVID-19 vaccine, which was first administered to health workers in Abuja.
The vaccination has been divided into phases. One of the phases includes the distribution of the vaccines to states that have met the requirements of storage and facilities.
As a result, the National Primary Health Care Development Agency (NPHCDA), which is the agency responsible for vaccines distribution strategy, budgeted N1.4billion for procurement of personal protective equipment (PPE) while N373m was set aside for adverse events following immunisation kits (AEFI kits).
However, the NGF appealed to the federal government to support the logistics and inoculation activities to states.
“Following extensive discussions on the vaccine administration, governors called on the Federal Government to take necessary steps to support logistics and inoculation activities in states and resolved to take the following actions to ensure a smooth vaccine roll-out exercise across the country,” Kayode Fayemi, chairman of NGF, noted in a communiqué.
“Upscale all vaccine communication and advocacy mechanisms already in place in the states to reduce the level of vaccination hesitancy amongst Nigerians;
“Provide adequate security to all state- and local government-owned cold stores that will be used for storing the vaccine.
“Ensure strict compliance and prioritisation of the list of eligible persons to be vaccinated, starting with all frontline workers, support staff, COVID-19 rapid response teams, workers in lab networks, isolation and treatment centres as well as tertiary and specialist hospitals.
“Strategic leaders will also be vaccinated to give confidence to the public on the safety of the vaccine. The second phase will prioritise older adults (50 and above) while the third and fourth phases will focus on adults (18-49) with co-morbidities such as hypertension, diabetes, lung disease, and other health conditions; and adults (18 – 49 years) without any underlying health condition and the rest of the population; actively monitor vaccine administration in their states through a vaccine implementation dashboard.”